TRAMAL 100MG/ML Perorální roztok Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

tramal 100mg/ml perorální roztok

stada arzneimittel ag, bad vilbel array - 2719 tramadol-hydrochlorid - perorální roztok - 100mg/ml - tramadol

TRAMAL 50MG Tvrdá tobolka Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

tramal 50mg tvrdá tobolka

stada arzneimittel ag, bad vilbel array - 2719 tramadol-hydrochlorid - tvrdá tobolka - 50mg - tramadol

TRAMAL 100MG Čípek Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

tramal 100mg Čípek

stada arzneimittel ag, bad vilbel array - 2719 tramadol-hydrochlorid - Čípek - 100mg - tramadol

TRAMAL 100MG/2ML Injekční roztok Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

tramal 100mg/2ml injekční roztok

stada arzneimittel ag, bad vilbel array - 2719 tramadol-hydrochlorid - injekční roztok - 100mg/2ml - tramadol

TRAMAL 50MG/ML Injekční roztok Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

tramal 50mg/ml injekční roztok

stada arzneimittel ag, bad vilbel array - 2719 tramadol-hydrochlorid - injekční roztok - 50mg/ml - tramadol

Sitagliptin SUN Evropská unie - čeština - EMA (European Medicines Agency)

sitagliptin sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Sitagliptin / Metformin hydrochloride Sun Evropská unie - čeština - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. trojkombinační léčbě) jako doplněk k dietním opatřením a cvičení u pacientů nedostatečně maximální tolerované dávky metforminu a sulfonylmočoviny. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Insuman Evropská unie - čeština - EMA (European Medicines Agency)

insuman

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - léky užívané při diabetu - diabetes mellitus, kde je nutná léčba inzulínem. insuman rapid je také vhodný pro zacházení s hyperglykemickým kómatem a ketoacidózy, stejně jako pro dosažení předem, intra - a pooperační stabilizace u pacientů s diabetes mellitus.